BridGene Biosciences

BridGene Biosciences is a biotechnology company founded in 2018, utilizing advanced chemoproteomic technology to discover and develop highly selective small molecules for traditionally undruggable targets. The company's slogan "Utilizing advanced chemoproteomic technology to discover and develop highly selective small molecules for traditionally undruggable targets" reflects its dedication to groundbreaking innovation in the biotechnology industry. BridGene Biosciences is dedicated to the discovery and development of novel small molecules, enabling covalent small molecules to perform proteome-wide screening in live cells. This process results in highly selective small molecules that target conventionally undruggable proteins, positioning the company at the forefront of the industry. BridGene Biosciences recently secured a significant $38.50M Series B investment on 27 July 2022, with key investors including Dyee Capital, Lapam Capital, Junson Capital. This infusion of capital signifies a strong show of support from leading venture capital firms, highlighting the potential and promise of BridGene Biosciences' innovative approach to biotechnology. With a focus on biotechnology and health and wellness industries, BridGene Biosciences is well-positioned to make a significant impact in the field with its pioneering chemoproteomic technology and targeted small molecule development.